241 related articles for article (PubMed ID: 30936145)
1. Hepatocyte-Specific Ablation or Whole-Body Inhibition of Xanthine Oxidoreductase in Mice Corrects Obesity-Induced Systemic Hyperuricemia Without Improving Metabolic Abnormalities.
Harmon DB; Mandler WK; Sipula IJ; Dedousis N; Lewis SE; Eckels JT; Du J; Wang Y; Huckestein BR; Pagano PJ; Cifuentes-Pagano E; Homanics GE; Van't Erve TJ; Stefanovic-Racic M; Jurczak MJ; O'Doherty RM; Kelley EE
Diabetes; 2019 Jun; 68(6):1221-1229. PubMed ID: 30936145
[TBL] [Abstract][Full Text] [Related]
2. Purine-Induced IFN-γ Promotes Uric Acid Production by Upregulating Xanthine Oxidoreductase Expression.
Wang H; Xie L; Song X; Wang J; Li X; Lin Z; Su T; Liang B; Huang D
Front Immunol; 2022; 13():773001. PubMed ID: 35154100
[TBL] [Abstract][Full Text] [Related]
3. Uric acid secretion from adipose tissue and its increase in obesity.
Tsushima Y; Nishizawa H; Tochino Y; Nakatsuji H; Sekimoto R; Nagao H; Shirakura T; Kato K; Imaizumi K; Takahashi H; Tamura M; Maeda N; Funahashi T; Shimomura I
J Biol Chem; 2013 Sep; 288(38):27138-27149. PubMed ID: 23913681
[TBL] [Abstract][Full Text] [Related]
4. Xanthine oxidoreductase activation is implicated in the onset of metabolic arthritis.
Aibibula Z; Ailixiding M; Iwata M; Piao J; Hara Y; Okawa A; Asou Y
Biochem Biophys Res Commun; 2016 Mar; 472(1):26-32. PubMed ID: 26903297
[TBL] [Abstract][Full Text] [Related]
5. Differential regulation of hypoxanthine and xanthine by obesity in a general population.
Furuhashi M; Koyama M; Higashiura Y; Murase T; Nakamura T; Matsumoto M; Sakai A; Ohnishi H; Tanaka M; Saitoh S; Moniwa N; Shimamoto K; Miura T
J Diabetes Investig; 2020 Jul; 11(4):878-887. PubMed ID: 31916414
[TBL] [Abstract][Full Text] [Related]
6. Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice.
Nishikawa T; Nagata N; Shimakami T; Shirakura T; Matsui C; Ni Y; Zhuge F; Xu L; Chen G; Nagashimada M; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S; Ota T
Sci Rep; 2020 Jan; 10(1):815. PubMed ID: 31965018
[TBL] [Abstract][Full Text] [Related]
7. The role of xanthine oxidoreductase and uric acid in metabolic syndrome.
Battelli MG; Bortolotti M; Polito L; Bolognesi A
Biochim Biophys Acta Mol Basis Dis; 2018 Aug; 1864(8):2557-2565. PubMed ID: 29733945
[TBL] [Abstract][Full Text] [Related]
8. Influence of xanthine oxidoreductase inhibitor, topiroxostat, on body weight of diabetic obese mice.
Nakamura T; Nampei M; Murase T; Satoh E; Akari S; Katoh N; Mizukami H
Nutr Diabetes; 2021 Apr; 11(1):12. PubMed ID: 33850106
[TBL] [Abstract][Full Text] [Related]
9. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.
Chen C; Lü JM; Yao Q
Med Sci Monit; 2016 Jul; 22():2501-12. PubMed ID: 27423335
[TBL] [Abstract][Full Text] [Related]
10. Mice heterozygous for the xanthine oxidoreductase gene facilitate lipid accumulation in adipocytes.
Murakami N; Ohtsubo T; Kansui Y; Goto K; Noguchi H; Haga Y; Nakabeppu Y; Matsumura K; Kitazono T
Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):44-51. PubMed ID: 24158515
[TBL] [Abstract][Full Text] [Related]
11. Enhanced XOR activity in eNOS-deficient mice: Effects on the nitrate-nitrite-NO pathway and ROS homeostasis.
Peleli M; Zollbrecht C; Montenegro MF; Hezel M; Zhong J; Persson EG; Holmdahl R; Weitzberg E; Lundberg JO; Carlström M
Free Radic Biol Med; 2016 Oct; 99():472-484. PubMed ID: 27609225
[TBL] [Abstract][Full Text] [Related]
12. Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in mice.
Yisireyili M; Hayashi M; Wu H; Uchida Y; Yamamoto K; Kikuchi R; Shoaib Hamrah M; Nakayama T; Wu Cheng X; Matsushita T; Nakamura S; Niwa T; Murohara T; Takeshita K
Sci Rep; 2017 Apr; 7(1):1266. PubMed ID: 28455534
[TBL] [Abstract][Full Text] [Related]
13. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity.
Furuhashi M
Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E827-E834. PubMed ID: 32893671
[TBL] [Abstract][Full Text] [Related]
14. Independent association of plasma xanthine oxidoreductase activity with hypertension in nondiabetic subjects not using medication.
Furuhashi M; Higashiura Y; Koyama M; Tanaka M; Murase T; Nakamura T; Akari S; Sakai A; Mori K; Ohnishi H; Saitoh S; Shimamoto K; Miura T
Hypertens Res; 2021 Sep; 44(9):1213-1220. PubMed ID: 34117403
[TBL] [Abstract][Full Text] [Related]
15. Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db/db mice.
Nakamura T; Murase T; Nampei M; Morimoto N; Ashizawa N; Iwanaga T; Sakamoto R
Eur J Pharmacol; 2016 Jun; 780():224-31. PubMed ID: 27038523
[TBL] [Abstract][Full Text] [Related]
16. Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions.
Orlicky DJ; Libby AE; Bales ES; McMahan RH; Monks J; La Rosa FG; McManaman JL
J Physiol; 2019 Mar; 597(6):1565-1584. PubMed ID: 30536914
[TBL] [Abstract][Full Text] [Related]
17. ABCG2 expression and uric acid metabolism of the intestine in hyperuricemia model rat.
Morimoto C; Tamura Y; Asakawa S; Kuribayashi-Okuma E; Nemoto Y; Li J; Murase T; Nakamura T; Hosoyamada M; Uchida S; Shibata S
Nucleosides Nucleotides Nucleic Acids; 2020; 39(5):744-759. PubMed ID: 31983315
[TBL] [Abstract][Full Text] [Related]
18. Xanthine oxidoreductase activity is correlated with insulin resistance and subclinical inflammation in young humans.
Washio KW; Kusunoki Y; Murase T; Nakamura T; Osugi K; Ohigashi M; Sukenaga T; Ochi F; Matsuo T; Katsuno T; Moriwaki Y; Yamamoto T; Namba M; Koyama H
Metabolism; 2017 May; 70():51-56. PubMed ID: 28403945
[TBL] [Abstract][Full Text] [Related]
19. Annual change in plasma xanthine oxidoreductase activity is associated with changes in liver enzymes and body weight.
Furuhashi M; Koyama M; Matsumoto M; Murase T; Nakamura T; Higashiura Y; Tanaka M; Moniwa N; Ohnishi H; Saitoh S; Shimamoto K; Miura T
Endocr J; 2019 Sep; 66(9):777-786. PubMed ID: 31130575
[TBL] [Abstract][Full Text] [Related]
20. Dispelling dogma and misconceptions regarding the most pharmacologically targetable source of reactive species in inflammatory disease, xanthine oxidoreductase.
Kelley EE
Arch Toxicol; 2015 Aug; 89(8):1193-207. PubMed ID: 25995007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
